Bhuvan Kishore

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Graham Jackson, Faith E. Davies, Charlotte Pawlyn et al. · The Lancet Oncology · 2018 · 332 citations · Full text

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

John R Jones, David A. Cairns, Walter M. Gregory et al. · Blood Cancer Journal · 2016 · 76 citations · Full text

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet

Eva Lengfelder, Francesco Lo‐Coco, Lionel Adès et al. · Leukemia · 2015 · 73 citations

Hematological Malignancy, Oncology, Arsenic Trioxide-based Therapy +9

Epstein‐Barr Virus–Associated Hemophagocytic Lymphohistiocytosis in Adults Characterized by High Viral Genome Load within Circulating Natural Killer Cells

Christopher P. Fox, C. Shannon‐Lowe, Philip Gothard et al. · Clinical Infectious Diseases · 2010 · 63 citations

Lymphoid Neoplasia, Autoimmune Disease, Epstein-barr Virus +14

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Graham Jackson, Faith E. Davies, Charlotte Pawlyn et al. · The Lancet Haematology · 2019 · 52 citations · Full text